Antwort

• Literatur

• 1 Murata N, Gonzalez-Cuyar LF, Murata K et al. Macrocyclic and other non-group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and bone tissue. Invest Radiol 2016; 51: 447-453
• 2 Kanda T, Fukusato T, Matsuda M et al. Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology 2015; 276: 228-232
• 3 Semelka RC, Ramalho M, AlObaidy M et al. Gadolinium in humans: A family of disorders. Am J Roentgenol 2016; 207: 229-233
• 4 Rogosnitzky M, Branch S. Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms. Biometals 2016; 29: 365-376
• 5 Gold R, Gass A, Haupts M et al. Therapieziele und Therapiemanagement bei schubförmig-remittierender Multipler Sklerose. Multiple Values Selected 2015; 34: 915-923
• 6 Lukas C, Sailer M. Magnetresonanztomografie bei Patienten mit Multipler Sklerose: Relevanz in der Diagnose und Verlaufsbeurteilung. Fortschr Neurol Psychiatr 2015; 83: 522-534
• 7 Sailer M, Fazekas F, Gass A et al. Zerebrale und spinale MRT-Untersuchung bei Patienten mit klinisch isoliertem Syndrom oder gesicherter Multipler Sklerose. Fortschr Röntgenstr 2008; 180: 994-1001
• 8 Rovira A, Wattjes MP, Tintoré M et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis – clinical implementation in the diagnostic process. Nat Rev Neurol 2015; 11: 471-482; erratum: 483
• 9 Wattjes MP, Rovira A, Miller D et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis – establishing disease prognosis and monitoring patients. Nat Rev Neurol 2015; 11: 597-606